Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Endocrinology›Condition·Updated Jul 11, 2026·v1

Diabetic Ketoacidosis

Diabetic ketoacidosis is an acute metabolic emergency characterized by hyperglycemia, ketosis, and metabolic acidosis, driven by insulin deficiency and counterregulatory hormone excess. Management follows a structured protocol: fluid resuscitation with balanced crystalloids, low-dose insulin therapy, potassium replacement, and selective bicarbonate use. Prevention of recurrence relies on continuous glucose monitoring, automated insulin delivery, and structured education. Early recognition and protocolized care reduce mortality to <1%.

High Evidence237 references·2,730 words·11 min read·v1
Diabetic KetoacidosisDKAHyperglycemic CrisisType 1 DiabetesKetosisEndocrinologyEmergency MedicineSGLT2 InhibitorsCerebral Edema

Quick Reference

RxDrug of choiceIV regular insulin: 0.1 U/kg bolus (optional) then 0.1 U/kg/h continuous infusion
AltAlternativesSubcutaneous rapid-acting insulin analogues (lispro, aspart) every 1-2 hours for mild DKA in monitored settings
⊘AvoidSGLT2 inhibitors during acute illness; routine bicarbonate; non-dihydropyridine CCBs
DxTest of choiceSerum β-hydroxybutyrate (≥3.0 mmol/L in children, ≥3.8 mmol/L in adults)
ScKey scoreDKA severity classification: mild (pH 7.25-7.30, bicarbonate 15-18), moderate (pH 7.0-7.24, bicarbonate 10-14), severe (pH <7.0, bicarbonate <10)
→When to referICU for severe DKA (pH <7.0, bicarbonate <5, altered mental status, hypotension); endocrinology for recurrent DKA, atypical presentation, or technology evaluation
DKA is a preventable metabolic crisis; early recognition, protocolized management with balanced fluids and low-dose insulin, and long-term use of CGM/AID reduce morbidity and mortality to <1%.
Diabetic ketoacidosis (DKA) is an acute metabolic emergency defined by hyperglycemia, ketosis, and metabolic acidosis, driven by insulin deficiency and counterregulatory hormone excess. It is the leading cause of hospitalization and death in children and young adults with type 1 diabetes. This concise reference summarizes diagnosis, severity classification, acute and long-term management, complications, and special populations, with key clinical pearls and actionable thresholds.

Overview and Recommendations

Background

  • •Diabetic ketoacidosis (DKA) is an acute metabolic emergency defined by the triad of hyperglycemia (>250 mg/dL), ketosis (serum β-hydroxybutyrate ≥3 mmol/L), and metabolic acidosis (pH <7.3, bicarbonate <15 mEq/L, anion gap >12). Absolute or relative insulin deficiency coupled with counterregulatory hormone excess (glucagon, catecholamines, cortisol) drives unchecked lipolysis, hepatic ketogenesis, and gluconeogenesis.
  • •DKA is the leading cause of hospitalization and death in children and young adults with type 1 diabetes. The 30-day all-cause readmission rate is 19.4%, and acute kidney injury complicates 37.8% of DKA hospitalizations, increasing mortality from 0.9% to 4.1%. In children, 41.9% of new-onset type 1 diabetes presents with DKA globally, with rates ranging from 15.6% in Sweden to 78.5% in Thailand.
  • •The syndrome encompasses multiple variants: classic autoimmune type 1 diabetes DKA, ketosis-prone type 2 diabetes (KPD) with preserved β-cell function and negative autoantibodies, euglycemic DKA (glucose <250 mg/dL) most often associated with use, immune checkpoint inhibitor-associated DKA (69.7% present with DKA), and fulminant type 1 diabetes with near-normal HbA1c. The Aβ classification system stratifies KPD by autoantibody status and β-cell reserve, predicting long-term insulin dependence.
  • •Incidence in established type 1 diabetes is 1.4-4.8 per 100 patient-years, with higher rates in adolescents, females, and those with lower socioeconomic status. The strongest iatrogenic risks come from (RR 2.23-2.59) and immune checkpoint inhibitors. Eating disorders confer a 3.3-fold increased DKA risk (HR 3.30) and a 6-fold increase in mortality. A prior DKA event is the single most actionable risk factor.
  • •The pathophysiology centers on a high glucagon-to-insulin ratio that activates hormone-sensitive lipase, releasing free fatty acids that the liver converts to ketone bodies (β-hydroxybutyrate, acetoacetate). (FABP4) is a necessary regulator of ketogenesis in insulin-deficient states; FABP4 levels correlate inversely with pH and bicarbonate. Hyperglycemia results from increased hepatic glucose output and reduced peripheral glucose utilization.

Evaluation

  • •Suspect DKA in any patient with polyuria, polydipsia, weight loss, nausea, vomiting, diffuse abdominal pain, Kussmaul respirations, or altered mental status. The classic triad of symptoms evolves over hours to days; abdominal pain can mimic an acute surgical abdomen.
  • •Ask about missed insulin doses, infection, use of or immune checkpoint inhibitors, pregnancy, recent surgery, alcohol use, or a history of eating disorders. In established type 1 diabetes, a prior DKA event is the strongest predictor.
  • •Examine for signs of dehydration (dry mucous membranes, reduced skin turgor, tachycardia), fruity acetone odor on breath, deep rapid breathing (Kussmaul respirations), and abdominal tenderness without peritonitis. Assess mental status using the ; lethargy, confusion, or coma correlate with severity of acidosis and hyperosmolality.
  • •In children, monitor for cerebral edema: headache, vomiting, bradycardia, hypertension, papilledema, or declining GCS. Cerebral edema typically develops 4-12 hours after treatment initiation but can be present at diagnosis.
  • •Order a venous blood gas (acceptable in place of arterial; venous pH is 0.02-0.05 units lower), serum glucose, electrolytes (including bicarbonate), BUN, creatinine, calculated anion gap, and serum osmolality. Point-of-care β-hydroxybutyrate is the preferred ketone measure; urine ketone dipsticks detect acetoacetate but not β-hydroxybutyrate and may underestimate ketosis.
  • •Diagnostic criteria: hyperglycemia >250 mg/dL (13.9 mmol/L); venous pH <7.3; serum bicarbonate <18 mmol/L; anion gap >10-12 mEq/L; serum β-hydroxybutyrate ≥3.0 mmol/L (children) or ≥3.8 mmol/L (adults). For euglycemic DKA, glucose may be <250 mg/dL, check ketones in any patient with unexplained high anion gap acidosis, especially those on SGLT2 inhibitors.
  • •Classify severity: mild (pH 7.25-7.30, bicarbonate 15-18 mmol/L), moderate (pH 7.0-7.24, bicarbonate 10-14 mmol/L), severe (pH <7.0, bicarbonate <10 mmol/L). Severe DKA, altered mental status, or hypotension warrants ICU admission.
  • •Identify the precipitating cause: history of missed insulin, infection, myocardial infarction, stroke, pancreatitis, alcohol, SGLT2i use, immune checkpoint inhibitor therapy, or pregnancy. Order chest radiography, ECG, lipase, cardiac biomarkers, and cultures as indicated.
  • •In new-onset adults, after stabilization check HbA1c, C-peptide, and islet autoantibodies (GAD65, IA-2, ZnT8) to classify diabetes type. Ketosis-prone type 2 diabetes is suggested by high BMI, , negative antibodies, and preserved C-peptide (>0.3 nmol/L).
  • •Consider mixed DKA- (HHS) when effective osmolality >320 mOsm/kg with DKA criteria; this combination carries an adjusted odds ratio of 2.7 for in-hospital mortality. Differential diagnoses include , uremia, and toxic ingestions, exclude by history, lactate level, and renal function.

Management

  • •Initiate fluid resuscitation first: administer 15-20 mL/kg of isotonic crystalloid over the first hour (typically 1 L in adults). The 2024 consensus recommends balanced crystalloids (e.g., lactated Ringer's) over 0.9% saline to reduce hyperchloremic acidosis. After the initial bolus, continue at 4-14 mL/kg/h based on corrected serum sodium and volume status, aiming to replace the deficit (6-8 L in adults) over 24-48 hours.
  • •Start intravenous regular insulin with a 0.1 U/kg bolus (optional) followed by 0.1 U/kg/h continuous infusion. A bolus is unnecessary if the infusion is started immediately. For mild DKA, subcutaneous rapid-acting insulin analogues (lispro, aspart) every 1-2 hours are a safe alternative in monitored settings.
  • •Replace potassium when serum K+ <5.3 mEq/L, aiming for 4-5 mEq/L. Add 20-30 mEq/L to each liter of IV fluid. If K+ <3.3 mEq/L, hold insulin and give 40 mEq/h until >3.3 mEq/L to avoid fatal arrhythmias. Severe hypokalemia (≤2.5 mEq/L) is associated with a 4.9-fold increase in mortality.
  • •Do NOT administer bicarbonate routinely. Use only if pH <6.9: 100 mmol NaHCO₃ in 400 mL sterile water over 2 hours for pH 6.9-7.0; 200 mmol over 2 hours for pH <6.9. Bicarbonate does not improve outcomes and may worsen hypokalemia and intracellular acidosis.
  • •Monitor glucose hourly until stable, then every 2 hours. Check electrolytes (Na, K, Cl, bicarbonate) every 2-4 hours. Measure β-hydroxybutyrate every 2-4 hours; resolution is defined as <0.3 mmol/L. Check venous pH every 2-4 hours until >7.3.
  • •When glucose falls to 200-250 mg/dL, reduce insulin infusion to 0.02-0.05 U/kg/h and add dextrose 5-10% to maintain glucose 150-200 mg/dL until ketoacidosis resolves. Do not stop insulin when glucose falls, add dextrose instead.
  • •DKA resolves when glucose <200 mg/dL, pH >7.3, bicarbonate >15 mEq/L, and anion gap normal. Transition to subcutaneous insulin when the patient is eating and the gap is closed. Overlap IV and SC insulin by 1-2 hours to prevent rebound hyperglycemia.
  • •Avoid: routine bicarbonate, stopping insulin when glucose falls, rapid correction of hyperosmolality (risk of ), and delaying insulin for hypokalemia (correct K+ first). Do not use non-dihydropyridine CCBs (diltiazem, verapamil) as they exacerbate metabolic acidosis.
  • •For SGLT2 inhibitor-associated DKA, hold the drug during acute illness and restart only after metabolic stability. These patients often present with euglycemic DKA, insulin and fluid therapy are the same; monitor ketones closely.
  • •Refer to ICU for severe DKA (pH <7.0, bicarbonate <5 mEq/L, altered mental status, hypotension, or combined DKA-HHS). Refer to endocrinology for recurrent DKA, atypical presentation, or consideration of advanced diabetes technology (CGM, automated insulin delivery).
  • •Discharge criteria: resolution of ketoacidosis, stable glucose on subcutaneous regimen, education on sick-day rules (including SGLT2i hold during illness), and follow-up with endocrinology within 2 weeks. Screen for psychosocial barriers (eating disorders, depression) and refer for diabetes self-management education.
  • •Long-term prevention: optimize insulin delivery with continuous glucose monitoring (CGM; reduces DKA risk by 60%) and automated insulin delivery (AID). Consider low-dose 2.5 mg as adjunct in selected type 1 diabetes patients with ketone monitoring. Screen first-degree relatives with islet autoantibody testing to identify presymptomatic type 1 diabetes and reduce DKA at onset to <5%.

Board Review — High Yield

  • •Euglycemic DKA, glucose <250 mg/dL, associated with SGLT2 inhibitor use; check serum ketones in any patient with high anion gap acidosis even if glucose is normal.
  • •Cerebral edema, most feared complication in children, occurs 4-12 hours after treatment initiation; avoid rapid osmolality correction; treat with mannitol 0.25-1 g/kg IV.
  • •Anion gap metabolic acidosis, closure of the gap indicates resolution; persistent gap after ketones normalize suggests concurrent [[lactic acidosis]] or other unmeasured anions.
  • •Ketosis-prone type 2 diabetes (KPD), autoantibody-negative, preserved C-peptide; often presents with DKA but may achieve insulin independence; look for [[acanthosis nigricans]] and obesity.
  • •Low-dose insulin therapy, 0.1 U/kg/h IV is standard; reduces hypoglycemia and hypokalemia risk compared to high-dose regimens (established by Fisher and Kitabchi 1977).
  • •Potassium replacement, hold insulin if K+ <3.3 mEq/L; severe hypokalemia (≤2.5 mEq/L) increases mortality 4.9-fold.
  • •Balanced crystalloids, preferred over 0.9% saline to reduce hyperchloremic acidosis; Cochrane meta-analysis shows lower mortality in critically ill adults.
  • •Automated insulin delivery (AID), reduces HbA1c by 0.8-1.5% and DKA risk by 60%; standard of care for type 1 diabetes in many guidelines.
  • •SGLT2 inhibitor DKA risk, dose-dependent; empagliflozin 2.5 mg has DKA rate comparable to placebo (0.8% vs 1.2%), while 10-25 mg increases risk to 3-4%.
  • •Screening for presymptomatic T1D, islet autoantibody screening reduces DKA at onset to 2.5% vs 40% in unscreened; cost-effective if DKA reduction ≥20%.

Deep Dive — Evidence Details

References

  1. [1]

    Wu L, Tsang V, Menzies AM et al.. “Risk Factors and Characteristics of Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes.” Diabetes care (2023). PMID: 37220262 ↗

    L2SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  2. [2]

    Marilly E, Cottin J, Cabrera N et al.. “SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.” Diabetologia (2022). PMID: 35925319 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  3. [3]

    Usher-Smith JA, Thompson M, Ercole A et al.. “Variation between countries in the frequency of diabetic ketoacidosis at first presentation of type 1 diabetes in children: a systematic review.” Diabetologia (2012). PMID: 22933123 ↗

    L2SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
  4. [4]

    Pruhova S, Dusatkova P, Neumann D et al.. “Two cases of diabetic ketoacidosis in HNF1A-MODY linked to severe dehydration: is it time to change the diagnostic criteria for MODY?” Diabetes care (2013). PMID: 23610083 ↗

    L4CASE_REPORTCited in: Definition, Classification and Axis Nomenclature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  5. [5]

    Raubenheimer PJ, Skelton J, Peya B et al.. “Phenotype and predictors of insulin independence in adults presenting with diabetic ketoacidosis: a prospective cohort study.” Diabetologia (2024). PMID: 38240751 ↗

    L2COHORTCited in: Definition, Classification and Axis Nomenclature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification
  6. [6]

    Shaka H, Aguilera M, Aucar M et al.. “Rate and Predictors of 30-day Readmission Following Diabetic Ketoacidosis in Type 1 Diabetes Mellitus: A US Analysis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34043791 ↗

    L2OTHERCited in: Definition, Classification and Axis Nomenclature
  7. [7]

    Jahoor F, Hsu JW, Keene KR et al.. “Amino Acids and CART Distinguish A-β+ Ketosis-Prone Diabetes From Type 1 and Type 2 Diabetes During Hyperglycemic Crises.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39820433 ↗

    L3OTHERCited in: Definition, Classification and Axis Nomenclature
  8. [8]

    Balasubramanyam A, Garza G, Rodriguez L et al.. “Accuracy and predictive value of classification schemes for ketosis-prone diabetes.” Diabetes care (2006). PMID: 17130187 ↗

    L2OTHERCited in: Definition, Classification and Axis Nomenclature
  9. [9]

    Hampp C, Swain RS, Horgan C et al.. “Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.” Diabetes care (2019). PMID: 31601640 ↗

    L2OTHERCited in: Definition, Classification and Axis Nomenclature
  10. [10]

    Sheikh-Ali M, Karon BS, Basu A et al.. “Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis?” Diabetes care (2008). PMID: 18184896 ↗

    L4OTHERCited in: Definition, Classification and Axis Nomenclature
  11. [11]

    Mulukutla SN, Acevedo-Calado M, Hampe CS et al.. “Autoantibodies to the IA-2 Extracellular Domain Refine the Definition of "A+" Subtypes of Ketosis-Prone Diabetes.” Diabetes care (2018). PMID: 30327357 ↗

    L2OTHERCited in: Definition, Classification and Axis Nomenclature
  12. [12]

    Chobot A, Bossowski A, Jarosz-Chobot P et al.. “Polish Recommendations for the Early Detection of Type 1 Diabetes in the Pediatric Population: A Position Statement of the Polish Society of Pediatric Endocrinology and Diabetology and the Pediatric Section of the Diabetes Poland 2026.” Hormone research in paediatrics (2026). PMID: 41999619 ↗

    L1GUIDELINECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  13. [13]

    Balasubramanyam A, Nalini R, Hampe CS et al.. “Syndromes of ketosis-prone diabetes mellitus.” Endocrine reviews (2008). PMID: 18292467 ↗

    L5CASE_REPORTCited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  14. [14]

    Kovacs A, Bunduc S, Veres DS et al.. “One third of cases of new-onset diabetic ketosis in adults are associated with ketosis-prone type 2 diabetes-A systematic review and meta-analysis.” Diabetes/metabolism research and reviews (2023). PMID: 37888894 ↗

    L2SR_OBSCited in: Definition, Classification and Axis Nomenclature
  15. [15]

    Delgado Moya FP, Antequera A, Muriel A et al.. “Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children.” The Cochrane database of systematic reviews (2026). PMID: 42011817 ↗

    L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  16. [16]

    Tian B, Chen C, Cheng J et al.. “Predictors, Morbidity, and Healthcare Costs of Acute Kidney Injury in Diabetic Ketoacidosis: A Decade-Long Retrospective Cohort Study of 464,057 US Hospitalizations.” Shock (Augusta, Ga.) (2025). PMID: 40550726 ↗

    L2COHORTCited in: Definition, Classification and Axis Nomenclature
  17. [17]

    Warncke K, Eckert A, Bonifacio E et al.. “Characterisation and clinical outcomes in children and adolescents with diabetes according to newly defined subgroups: a cohort study from the DPV registry.” EClinicalMedicine (2023). PMID: 37731934 ↗

    L2COHORTCited in: Definition, Classification and Axis Nomenclature
  18. [18]

    Zhang X, Huang D, Lou D et al.. “Stevens-Johnson Syndrome/Toxic epidermal necrolysis complicated with fulminant type 1 diabetes mellitus: a case report and literature review.” BMC endocrine disorders (2024). PMID: 39218880 ↗

    L4CASE_REPORTCited in: Definition, Classification and Axis Nomenclature
  19. [19]

    Fisker FA, Voss TS, Svart MV et al.. “Insulin Signaling Is Preserved in Skeletal Muscle During Early Diabetic Ketoacidosis.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37554078 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  20. [20]

    Boeder SC, Thomas RL, Le Roux MJ et al.. “Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial.” Diabetes care (2025). PMID: 38776437 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  21. [21]

    Lee TTM, Collett C, Bergford S et al.. “Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes.” The New England journal of medicine (2023). PMID: 37796241 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  22. [22]

    de Filette JMK, Pen JJ, Decoster L et al.. “Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.” European journal of endocrinology (2019). PMID: 31330498 ↗

    L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  23. [23]

    Bangshaab M, Svart MV, Rittig N et al.. “Metabolic effects of 3-hydroxybutyrate infusion in individuals with type 1 diabetes compared with healthy control participants: a randomised crossover trial showing intact feedback suppression of lipolysis.” Diabetologia (2025). PMID: 40210728 ↗

    L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
  24. [24]

    Colombijn JMT, de Leijer JF, Visseren FLJ et al.. “Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies.” Diabetologia (2025). PMID: 41117973 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  25. [25]

    Willard D, Upadhyay J, Kim C et al.. “Diabetic Ketoacidosis Without Diabetes.” The Journal of clinical endocrinology and metabolism (2016). PMID: 27636019 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  26. [26]

    Clotman K, Janssens K, Specenier P et al.. “Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29955867 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  27. [27]

    Sakuma I, Higuchi S, Fujimoto M et al.. “Cushing Syndrome Due to ACTH-Secreting Pheochromocytoma, Aggravated by Glucocorticoid-Driven Positive-Feedback Loop.” The Journal of clinical endocrinology and metabolism (2015). PMID: 26700559 ↗

    L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
  28. [28]

    Kitabchi AE, Umpierrez GE, Fisher JN et al.. “Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18270259 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  29. [29]

    Burckhardt MA, Gotta V, Beglinger S et al.. “Copeptin Kinetics and Its Relationship to Osmolality During Rehydration for Diabetic Ketoacidosis in Children.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32835363 ↗

    L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  30. [30]

    Edwards K, Li X, Lingvay I. “Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36268825 ↗

    L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
  31. [31]

    Umpierrez GE, Davis GM, ElSayed NA et al.. “Hyperglycemic Crises in Adults With Diabetes: A Consensus Report.” Diabetes care (2024). PMID: 39052901 ↗

    L1REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  32. [32]

    Agiostratidou G, Anhalt H, Ball D et al.. “Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange.” Diabetes care (2017). PMID: 29162582 ↗

    L1REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Special Populations, Pregnancy and Fertility
  33. [33]

    Wilding JP, Rajeev SP, DeFronzo RA. “Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.” Diabetes care (2016). PMID: 27440828 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
  34. [34]

    Patorno E, Pawar A, Bessette LG et al.. “Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.” Diabetes care (2021). PMID: 33495295 ↗

    L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  35. [35]

    Haaland WC, Scaduto DI, Maldonado MR et al.. “A-beta-subtype of ketosis-prone diabetes is not predominantly a monogenic diabetic syndrome.” Diabetes care (2009). PMID: 19228875 ↗

    L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  36. [36]

    Knip M, Parviainen A, Turtinen M et al.. “SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study.” The lancet. Diabetes & endocrinology (2023). PMID: 36958868 ↗

    L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Special Populations, Pregnancy and Fertility
  37. [37]

    Bugbee A, Rucinsky R, Alvarez E et al.. “2026 AAHA Diabetes Management Guidelines for Cats.” Journal of the American Animal Hospital Association (2026). PMID: 42014100 ↗

    L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
  38. [38]

    Brown E, Heerspink HJL, Cuthbertson DJ et al.. “SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.” Lancet (London, England) (2021). PMID: 34216571 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  39. [39]

    Moreno-Pérez Ó, Tejera-Muñoz A, Leiva-Mora N et al.. “Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study.” Cardiovascular diabetology (2026). PMID: 41913157 ↗

    L2TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors
  40. [40]

    Umpierrez GE, Davis GM, ElSayed NA et al.. “Hyperglycaemic crises in adults with diabetes: a consensus report.” Diabetologia (2024). PMID: 38907161 ↗

    L1OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  41. [41]

    Anson M, Zhao SS, Austin P et al.. “SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.” Diabetologia (2023). PMID: 37505282 ↗

    L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  42. [42]

    McCrimmon RJ, Henry RR. “SGLT inhibitor adjunct therapy in type 1 diabetes.” Diabetologia (2018). PMID: 30132030 ↗

    L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
  43. [43]

    Gruber N, Rathaus M, Ron I et al.. “Fatty acid-binding protein 4: a key regulator of ketoacidosis in new-onset type 1 diabetes.” Diabetologia (2021). PMID: 34806114 ↗

    L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  44. [44]

    Sun WT, Liu RX, Jiang YH et al.. “Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.” Diabetes, obesity & metabolism (2026). PMID: 42426564 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  45. [45]

    Wójcik-Sosnowska E, Tabeau A, Pawlik A et al.. “Metabolic Benefits vs. Cardiovascular Uncertainty: A Critical Review of GLP-1 Receptor Agonists in Type 1 Diabetes.” International journal of molecular sciences (2026). PMID: 42123472 ↗

    L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  46. [46]

    Kateel R, Parida A, Chogtu B et al.. “Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 42105869 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  47. [47]

    Zhou Y, Lei M, Lin Q et al.. “Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors as Adjunctive Therapy to Automated Insulin Delivery System in Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.” Diabetes technology & therapeutics (2026). PMID: 41640116 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification
  48. [48]

    Abdel-Rahman SM, Al-Shiab R, Shah E et al.. “Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis.” Diabetes, obesity & metabolism (2026). PMID: 41605813 ↗

    L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
  49. [49]

    Rivetti G, Braile M, Di Sessa A et al.. “Acute Kidney Injury in Children with Polyuria: A Systematic Review.” Journal of clinical medicine (2026). PMID: 41517599 ↗

    L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  50. [50]

    Natale P, Green SC, Tunnicliffe DJ et al.. “Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes.” The Cochrane database of systematic reviews (2025). PMID: 41263251 ↗

    L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  51. [51]

    Lin DS, Lee JK, Chen WJ. “Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33895840 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  52. [52]

    McGurnaghan SJ, Weir A, Bishop J et al.. “Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland.” The lancet. Diabetes & endocrinology (2020). PMID: 33357491 ↗

    L2RCTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
  53. [53]

    Kuppermann N, Ghetti S, Schunk JE et al.. “Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.” The New England journal of medicine (2018). PMID: 29897851 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  54. [54]

    Thomas M, Harjutsalo V, Feodoroff M et al.. “The Long-Term Incidence of Hospitalization for Ketoacidosis in Adults with Established T1D-A Prospective Cohort Study.” The Journal of clinical endocrinology and metabolism (2020). PMID: 31529090 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Prognosis, Natural History and Prevention
  55. [55]

    Rosager EV, Heltø ALK, Fox Maule CU et al.. “Incidence and Characteristics of the Hyperosmolar Hyperglycemic State: A Danish Cohort Study.” Diabetes care (2024). PMID: 38085699 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
  56. [56]

    Basu S, Zafra-Tanaka JH, Beran D. “Type 1 diabetes intervention clusters in resource-limited settings: a systematic review and economic evaluation.” The lancet. Diabetes & endocrinology (2026). PMID: 42140211 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  57. [57]

    Wu CY, Sharma A, Edwards JD et al.. “Cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP4 inhibitors by dementia status: a cohort study of older adults with diabetes.” Diabetologia (2025). PMID: 41204979 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  58. [58]

    Dhanasekaran M, Mohan S, Erickson D et al.. “Diabetic Ketoacidosis in Pregnancy: Clinical Risk Factors, Presentation, and Outcomes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35917830 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management and Endocrine Emergencies, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  59. [59]

    Fleming N, Hamblin PS, Story D et al.. “Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32302001 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  60. [60]

    Sooy M, Pyle L, Alonso GT et al.. “Lower Prevalence of Diabetic Ketoacidosis at Diagnosis in Research Participants Monitored for Hyperglycemia.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38470864 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification
  61. [61]

    Beck RW, Tamborlane WV, Bergenstal RM et al.. “The T1D Exchange clinic registry.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22996145 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  62. [62]

    Pasquel FJ, Umpierrez GE. “Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment.” Diabetes care (2014). PMID: 25342831 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  63. [63]

    Khunti K, Del Prato S, Mathieu C et al.. “COVID-19, Hyperglycemia, and New-Onset Diabetes.” Diabetes care (2021). PMID: 34625431 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  64. [64]

    Bakhsh A, Saleemi A, Budhram D et al.. “Chronic Kidney Disease and Risk of Diabetic Ketoacidosis in Type 1 Diabetes.” Diabetes care (2026). PMID: 41591367 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  65. [65]

    Gibbings NK, Kurdyak PA, Colton PA et al.. “Diabetic Ketoacidosis and Mortality in People With Type 1 Diabetes and Eating Disorders.” Diabetes care (2021). PMID: 34172488 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
  66. [66]

    Polcwiartek C, Kragholm K, Rohde C et al.. “Diabetic ketoacidosis and diabetes associated with antipsychotic exposure among a previously diabetes-naive population with schizophrenia: a nationwide nested case-control study.” Diabetologia (2017). PMID: 28593353 ↗

    L3CASE_CONTROLCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  67. [67]

    Stephens JW, Dhatariya K, Beamish AJ et al.. “Diabetes management in people undergoing metabolic-bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Group.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41840846 ↗

    L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  68. [68]

    Yoshida N, Goto H, Suzuki H et al.. “Ketoacidosis as the initial clinical condition in nine patients with acromegaly: a review of 860 cases at a single institute.” European journal of endocrinology (2013). PMID: 23828957 ↗

    L4REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  69. [69]

    Karges B, Rosenbauer J, Holterhus PM et al.. “Hospital admission for diabetic ketoacidosis or severe hypoglycemia in 31,330 young patients with type 1 diabetes.” European journal of endocrinology (2015). PMID: 26088822 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  70. [70]

    Ehrmann D, Kulzer B, Roos T et al.. “Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes.” The lancet. Diabetes & endocrinology (2020). PMID: 32333879 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  71. [71]

    Apicella M, Campopiano MC, Mantuano M et al.. “COVID-19 in people with diabetes: understanding the reasons for worse outcomes.” The lancet. Diabetes & endocrinology (2020). PMID: 32687793 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  72. [72]

    Karges B, Rosenbauer J, Stahl-Pehe A et al.. “Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2-20 years) with type 1 diabetes: a population-based study.” The lancet. Diabetes & endocrinology (2024). PMID: 39701114 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
  73. [73]

    Ward ZJ, Yeh JM, Reddy CL et al.. “Estimating the total incidence of type 1 diabetes in children and adolescents aged 0-19 years from 1990 to 2050: a global simulation-based analysis.” The lancet. Diabetes & endocrinology (2022). PMID: 36372070 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
  74. [74]

    Sweety S, Panda S, Das RR. “Balanced electrolyte solution vs isotonic saline in the resuscitation of children with diabetic ketoacidosis: A randomized controlled trial.” World journal of clinical pediatrics (2026). PMID: 41884024 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Special Populations, Pregnancy and Fertility
  75. [75]

    Khunti K, Valabhji J, Misra S. “Diabetes and the COVID-19 pandemic.” Diabetologia (2022). PMID: 36418578 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  76. [76]

    Martinenghi S, Merolla A, Grogan P et al.. “Prevention of diabetic ketoacidosis in relatives screened for islet autoantibodies and followed up in the TrialNet Pathway to Prevention study at a single institution in Italy.” Diabetologia (2025). PMID: 40439773 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, History and Evolution of Treatment, Prognosis, Natural History and Prevention
  77. [77]

    Zhang T, Zhang H, Huang S et al.. “Worldwide prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes: A systematic review and meta-analysis.” Preventive medicine (2026). PMID: 42303108 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  78. [78]

    Carlsson A, Shepherd M, Ellard S et al.. “Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study.” Diabetes care (2019). PMID: 31704690 ↗

    L2COHORTCited in: Clinical Presentation
  79. [79]

    Cameron FJ, Scratch SE, Nadebaum C et al.. “Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children.” Diabetes care (2014). PMID: 24855156 ↗

    L2COHORTCited in: Clinical Presentation
  80. [80]

    Eliades M, El-Maouche D, Choudhary C et al.. “Takotsubo cardiomyopathy associated with thyrotoxicosis: a case report and review of the literature.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23560557 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
  81. [81]

    Oak S, Gaur LK, Radtke J et al.. “Masked and overt autoantibodies specific to the DPD epitope of 65-kDa glutamate decarboxylase (GAD65-DPD) are associated with preserved β-cell functional reserve in ketosis-prone diabetes.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24601691 ↗

    L2OTHERCited in: Clinical Presentation
  82. [82]

    Karakus KE, Fleury T, Baschal EE et al.. “Clinical Features and HLA Genetics Differ in Children at Type 1 Diabetes Onset by Hispanic Ethnicity.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39231249 ↗

    L3OTHERCited in: Clinical Presentation
  83. [83]

    Wu L, Carlino MS, Brown DA et al.. “Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37997380 ↗

    L4OTHERCited in: Clinical Presentation
  84. [84]

    Suzuki S, Makita Y, Mukai T et al.. “Molecular basis of neonatal diabetes in Japanese patients.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17635943 ↗

    L4OTHERCited in: Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  85. [85]

    Denson AM, Rodriguez KE, Letourneau-Freiberg LR et al.. “Children With Pancreatic Hypoplasia Experience Poor Weight Gain and Labile Diabetes but Low Incidence of DKA.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41006196 ↗

    L3OTHERCited in: Clinical Presentation, History and Evolution of Treatment
  86. [86]

    Byun DJ, Braunstein R, Flynn J et al.. “Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience.” Diabetes care (2020). PMID: 33051330 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  87. [87]

    Sasidharan Pillai S, Has P, Quintos JB et al.. “Incidence, Severity, and Presentation of Type 2 Diabetes in Youth During the First and Second Year of the COVID-19 Pandemic.” Diabetes care (2023). PMID: 36637859 ↗

    L3OTHERCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  88. [88]

    Hummel S, Carl J, Friedl N et al.. “Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation.” Diabetologia (2023). PMID: 37329450 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History and Prevention
  89. [89]

    Perry RJ, Petersen KF, Shulman GI. “Pleotropic effects of leptin to reverse insulin resistance and diabetic ketoacidosis.” Diabetologia (2016). PMID: 26961503 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  90. [90]

    Katte JC, Bavuma C, Wild SH et al.. “Atypical diabetes subtypes in Black African populations.” Diabetologia (2026). PMID: 41770244 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
  91. [91]

    Haddad N, Farhat N, Gravel CA et al.. “Antipsychotic Drugs and the Risk of Diabetic Complications: A Systematic Review of Clinical Evidence.” Journal of clinical medicine (2026). PMID: 42074909 ↗

    L4SR_OBSCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  92. [92]

    Alsulaimi NMA. “Euglycemic diabetic ketoacidosis following sleeve gastrectomy in a patient with type 2 diabetes on a sodium-glucose co-transporter 2 inhibitor: a case report and call for practice guidelines.” AME case reports (2026). PMID: 41676203 ↗

    L4GUIDELINECited in: Clinical Presentation
  93. [93]

    Casalini E, Puliti D, Piccini B et al.. “Natural history of a pediatric cohort with islet autoantibody positivity: a single-center retrospective cohort study.” Journal of the Endocrine Society (2026). PMID: 42063580 ↗

    L3COHORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification
  94. [94]

    Alqahtani YA, Shati AA, Alshaikh AA et al.. “Prevalence and Recovery of Euthyroid Sick Syndrome in Pediatric Diabetic Ketoacidosis: A Retrospective Cohort Study.” Children (Basel, Switzerland) (2026). PMID: 41749652 ↗

    L3COHORTCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  95. [95]

    Itagaki H, Endo T. “Acute esophageal necrosis in patients with diabetic ketoacidosis: a systematic review of clinical features and outcomes.” Clinical journal of gastroenterology (2026). PMID: 42406282 ↗

    L4SR_OBSCited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  96. [96]

    Ngo EMT, Rowe JM, Chillon TS et al.. “Type B insulin resistance with glycemic extremes: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 42255432 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  97. [97]

    He M, Zheng Z, Guo X et al.. “Immune checkpoint inhibitor-associated diabetes mellitus: an overlooked immune-related adverse event-two case reports and a literature review.” Frontiers in immunology (2026). PMID: 42183192 ↗

    L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment
  98. [98]

    Choudhary P, Kolassa R, Keuthage W et al.. “Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study.” The lancet. Diabetes & endocrinology (2022). PMID: 36058207 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  99. [99]

    Wilmot EG, Beltrand J, Guerci B et al.. “Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial.” The lancet. Diabetes & endocrinology (2026). PMID: 41747751 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  100. [100]

    Beck RW, Riddlesworth TD, Ruedy KJ et al.. “Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial.” The lancet. Diabetes & endocrinology (2017). PMID: 28711468 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment
  101. [101]

    Wadwa RP, Reed ZW, Buckingham BA et al.. “Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.” The New England journal of medicine (2023). PMID: 36920756 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  102. [102]

    Russell SJ, Beck RW, Damiano ER et al.. “Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36170500 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  103. [103]

    Boughton CK, Allen JM, Ware J et al.. “Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36069870 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  104. [104]

    Teo E, Hassan N, Tam W et al.. “Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis.” Diabetologia (2022). PMID: 35141761 ↗

    L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies
  105. [105]

    Tauschmann M, Thabit H, Bally L et al.. “Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.” Lancet (London, England) (2018). PMID: 30292578 ↗

    L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History and Prevention
  106. [106]

    Kim JY, Kim S, Kim JH. “Continuous glucose monitoring and risks of acute and chronic diabetes-related complications and mortality in adults with type 1 diabetes: a nationwide cohort study.” Diabetologia (2026). PMID: 41865177 ↗

    L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  107. [107]

    Gleeson H, Amin R, Maghnie M. “'Do no harm': management of craniopharyngioma.” European journal of endocrinology (2008). PMID: 18775978 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  108. [108]

    Prahalad P, Zaharieva D, Maahs DM. “Diabetes technology: an update.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41973910 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  109. [109]

    Palermo NE, Sadhu AR, McDonnell ME. “Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32556147 ↗

    L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  110. [110]

    Cao S, Cao S. “Hyperglycemic Hypernatremic Hypertonic State: A Predominant HHS Subtype and Its Clinical and Diagnostic Features.” The Journal of clinical endocrinology and metabolism (2026). PMID: 40690721 ↗

    L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  111. [111]

    Lahoti A, Haque MR, Bianco ME et al.. “Trends of Diabetes in Youth (TrenDY) During COVID-19 Across the United States.” The Journal of clinical endocrinology and metabolism (2026). PMID: 40658807 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  112. [112]

    Wright JJ, Johnson DB. “Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36481794 ↗

    L5OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification
  113. [113]

    Okada A, Yamana H, Morita K et al.. “Potassium Concentration in Initial Fluid Therapy and In-Hospital Mortality of Patients with Diabetic Ketoacidosis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33493293 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  114. [114]

    Shi Y, Shen M, Zheng X et al.. “ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32905579 ↗

    L4REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  115. [115]

    Wang Y, Qin Y, Gu H et al.. “High Residual β-cell Function in Chinese Patients With Autoimmune Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35218654 ↗

    L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  116. [116]

    Phillip M, Achenbach P, Addala A et al.. “Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes.” Diabetes care (2024). PMID: 38912694 ↗

    L5OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  117. [117]

    Holt RIG, DeVries JH, Hess-Fischl A et al.. “The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).” Diabetes care (2021). PMID: 34593612 ↗

    L1REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  118. [118]

    Hedlund E, Maziarz M, Lindahl T et al.. “Clinical Characteristics in Swedish Children With and Without Autoantibodies at the Time of Type 1 Diabetes Diagnosis.” Diabetes care (2025). PMID: 41091947 ↗

    L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  119. [119]

    Kilpatrick ES, Butler AE, Ostlundh L et al.. “Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis.” Diabetes care (2022). PMID: 35050366 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification
  120. [120]

    Alonso GT, Coakley A, Pyle L et al.. “Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Colorado Children, 2010-2017.” Diabetes care (2019). PMID: 31601639 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Special Populations, Pregnancy and Fertility
  121. [121]

    Dovc K, Neuman V, Gita G et al.. “Association of Diabetic Ketoacidosis at Onset, Diabetes Technology Uptake, and Clinical Outcomes After 1 and 2 Years of Follow-up: A Collaborative Analysis of Pediatric Registries Involving 9,269 Children With Type 1 Diabetes From Nine Countries.” Diabetes care (2025). PMID: 39965057 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Special Populations, Pregnancy and Fertility
  122. [122]

    Hekkala A, Ilonen J, Knip M et al.. “Family history of diabetes and distribution of class II HLA genotypes in children with newly diagnosed type 1 diabetes: effect on diabetic ketoacidosis.” European journal of endocrinology (2011). PMID: 21890652 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, History and Evolution of Treatment
  123. [123]

    Marigliano M, Morandi A, Maschio M et al.. “Diabetic ketoacidosis at diagnosis: role of family history and class II HLA genotypes.” European journal of endocrinology (2012). PMID: 23065995 ↗

    L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, History and Evolution of Treatment
  124. [124]

    Lin Q, Zhou Y, Lei M et al.. “Efficacy and safety of automated insulin delivery system in very young children with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42108409 ↗

    L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  125. [125]

    Thomas NJ, Jones SE, Weedon MN et al.. “Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank.” The lancet. Diabetes & endocrinology (2017). PMID: 29199115 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
  126. [126]

    Karges B, Tittel SR, Bey A et al.. “Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-based study.” The lancet. Diabetes & endocrinology (2023). PMID: 37004710 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  127. [127]

    Birkebaek NH, Kamrath C, Grimsmann JM et al.. “Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries.” The lancet. Diabetes & endocrinology (2022). PMID: 36202118 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification
  128. [128]

    Sun Q, Zhao G. “The Efficacy and Safety of Teplizumab in the Treatment of Stage 3 Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Diabetes, metabolic syndrome and obesity : targets and therapy (2026). PMID: 42221148 ↗

    L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  129. [129]

    Ziegler AG, Cengiz E, Kay TWH. “The future of type 1 diabetes therapy.” Lancet (London, England) (2025). PMID: 40983070 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  130. [130]

    Holt RIG, DeVries JH, Hess-Fischl A et al.. “The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).” Diabetologia (2021). PMID: 34590174 ↗

    L1OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  131. [131]

    Phillip M, Achenbach P, Addala A et al.. “Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes.” Diabetologia (2024). PMID: 38910151 ↗

    L1OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
  132. [132]

    Marcovecchio ML, Hendriks AEJ, Delfin C et al.. “The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults.” Diabetologia (2024). PMID: 38517484 ↗

    L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
  133. [133]

    He L, Chen L, Liu C. “Rapid-onset respiratory failure caused by diabetic ketoacidosis complicated with pulmonary mucormycosis: a case report and literature review.” Frontiers in medicine (2026). PMID: 42232973 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  134. [134]

    Xiao Q, Zhao Y, Du J et al.. “Oral myiasis complicating endotracheal intubation in a diabetic patient: a case report.” Frontiers in endocrinology (2026). PMID: 42222065 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
  135. [135]

    Bhat SZ, Wu J, Perin J et al.. “Effectiveness of Dexamethasone for COVID-19 in Hospitalized Patients With Diabetes: A Retrospective Cohort Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39418352 ↗

    L2COHORTCited in: Severity, Staging and Risk Stratification, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  136. [136]

    Pasquel FJ, Tsegka K, Wang H et al.. “Clinical Outcomes in Patients With Isolated or Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State: A Retrospective, Hospital-Based Cohort Study.” Diabetes care (2019). PMID: 31704689 ↗

    L2COHORTCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  137. [137]

    Hartmann-Boyce J, Highton P, Rees K et al.. “The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review.” The lancet. Diabetes & endocrinology (2024). PMID: 38272607 ↗

    L2SR_OBSCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
  138. [138]

    Yousif MF, Dolak KD, Adhikari S et al.. “A Nested Case-Control Study of Adverse Outcomes in Children With Diabetic Ketoacidosis.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39657257 ↗

    L3CASE_CONTROLCited in: Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  139. [139]

    Yousif MF, Dolak KD, Adhikari S et al.. “Risk Factors for Adverse Outcomes in Children With Diabetic Ketoacidosis.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39031569 ↗

    L2OTHERCited in: Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  140. [140]

    Everett EM, Copeland TP, Moin T et al.. “Insulin Pump-related Inpatient Admissions in a National Sample of Youth With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35196382 ↗

    L2OTHERCited in: Severity, Staging and Risk Stratification, Special Populations, Pregnancy and Fertility
  141. [141]

    Rabbone I, Schiaffini R, Cherubini V et al.. “Has COVID-19 Delayed the Diagnosis and Worsened the Presentation of Type 1 Diabetes in Children?” Diabetes care (2020). PMID: 32778554 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification
  142. [142]

    Aye T, Mazaika PK, Mauras N et al.. “Impact of Early Diabetic Ketoacidosis on the Developing Brain.” Diabetes care (2018). PMID: 30573652 ↗

    L2OTHERCited in: Severity, Staging and Risk Stratification, History and Evolution of Treatment, Prognosis, Natural History and Prevention
  143. [143]

    Edge JA, Jakes RW, Roy Y et al.. “The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children.” Diabetologia (2006). PMID: 16847700 ↗

    L3CASE_CONTROLCited in: Severity, Staging and Risk Stratification
  144. [144]

    Li Y, Chen J, Gao Y et al.. “Comparative Safety of SGLT2 Versus DPP4 Inhibitors in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.” Diabetes therapy : research, treatment and education of diabetes and related disorders (2026). PMID: 41678006 ↗

    L1SR_MA_RCTCited in: Severity, Staging and Risk Stratification, History and Evolution of Treatment
  145. [145]

    Gilbert BW, Turpin BB, Murray DS et al.. “The Evaluation of Early Basal Insulin in Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis.” Diabetes/metabolism research and reviews (2026). PMID: 41865288 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification
  146. [146]

    Sebastian-Valles F, Sampedro-Nuñez MA, Arranz-Martin JA et al.. “Pre- and in-hospital lactate ratio as a predictor of mortality in severe diabetic ketoacidosis: a multicenter prospective cohort study.” European journal of internal medicine (2026). PMID: 41521082 ↗

    L2COHORTCited in: Severity, Staging and Risk Stratification
  147. [147]

    Wang Z, Zhang Y, Yang H et al.. “Prevalence and prognostic impact of rhabdomyolysis in adults hospitalized with diabetic ketosis: a 10-year single-center cohort study.” Endocrine connections (2026). PMID: 41670427 ↗

    L2COHORTCited in: Severity, Staging and Risk Stratification
  148. [148]

    Rosenstock J, Marquard J, Laffel LM et al.. “Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.” Diabetes care (2018). PMID: 30287422 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  149. [149]

    Tamborlane WV, Laffel LM, Shehadeh N et al.. “Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.” The lancet. Diabetes & endocrinology (2022). PMID: 35378069 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  150. [150]

    von Herrath M, Bain SC, Bode B et al.. “Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.” The lancet. Diabetes & endocrinology (2021). PMID: 33662334 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  151. [151]

    Battelino T, Kuusela S, Shetty A et al.. “Efficacy and safety of automated insulin delivery in children aged 2-6 years (LENNY): an open-label, multicentre, randomised, crossover trial.” The lancet. Diabetes & endocrinology (2025). PMID: 40544853 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  152. [152]

    Wiviott SD, Raz I, Bonaca MP et al.. “Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.” The New England journal of medicine (2018). PMID: 30415602 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  153. [153]

    Bhatt DL, Szarek M, Pitt B et al.. “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The New England journal of medicine (2020). PMID: 33200891 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
  154. [154]

    Brown SA, Kovatchev BP, Raghinaru D et al.. “Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.” The New England journal of medicine (2019). PMID: 31618560 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  155. [155]

    Burnside MJ, Lewis DM, Crocket HR et al.. “Open-Source Automated Insulin Delivery in Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36069869 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  156. [156]

    Elbarbary NS, Ismail EA, El-Hamamsy MH et al.. “The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial.” Diabetologia (2024). PMID: 39271520 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  157. [157]

    Taylor SI, Blau JE, Rother KI. “SGLT2 Inhibitors May Predispose to Ketoacidosis.” The Journal of clinical endocrinology and metabolism (2015). PMID: 26086329 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies
  158. [158]

    Leichter SB, Felton JL, Geno Rasmussen C et al.. “Establishing Screening Programs for Presymptomatic Type 1 Diabetes: Practical Guidance for Diabetes Care Providers.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40171881 ↗

    L5OTHERCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  159. [159]

    Wang Y, Guo H, Wang G et al.. “COVID-19 as a Trigger for Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36950864 ↗

    L5OTHERCited in: Acute Management and Endocrine Emergencies
  160. [160]

    Tian Y, Qiu Z, Wang F et al.. “Associations of Diabetes and Prediabetes With Mortality and Life Expectancy in China: A National Study.” Diabetes care (2024). PMID: 39255435 ↗

    L2OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  161. [161]

    Chantzichristos D, Eliasson B, Johannsson G. “MANAGEMENT OF ENDOCRINE DISEASE Disease burden and treatment challenges in patients with both Addison's disease and type 1 diabetes mellitus.” European journal of endocrinology (2020). PMID: 32299062 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  162. [162]

    Lei M, Lin Q, Zhou Y et al.. “Efficacy and Safety of Tubeless Hybrid Closed-Loop Systems in Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials.” Diabetes, obesity & metabolism (2026). PMID: 42410321 ↗

    L1SR_MA_RCTCited in: Acute Management and Endocrine Emergencies
  163. [163]

    Dhatariya K, Bergenstal RM, Al-Sofiani M et al.. “Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology.” The lancet. Diabetes & endocrinology (2026). PMID: 41381175 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  164. [164]

    Zimmermann AT, Lanzinger S, Kummernes SJ et al.. “Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013-22): a longitudinal analysis of data from paediatric diabetes registries.” The lancet. Diabetes & endocrinology (2024). PMID: 39622257 ↗

    L2OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  165. [165]

    Sabelli N, Pasqua MR, Perz N et al.. “Transient Benign Ketosis Is Common in Type 1 Diabetes During Very-Low Carbohydrate States: Novel Data from Continuous Ketone Sensor.” Diabetes technology & therapeutics (2026). PMID: 42381172 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  166. [166]

    Cameron FJ, Wherrett DK. “Care of diabetes in children and adolescents: controversies, changes, and consensus.” Lancet (London, England) (2015). PMID: 26009230 ↗

    L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  167. [167]

    Htoo PT, Tesfaye H, Schneeweiss S et al.. “Effectiveness and safety of empagliflozin: final results from the EMPRISE study.” Diabetologia (2024). PMID: 38509341 ↗

    L2OTHERCited in: Acute Management and Endocrine Emergencies, History and Evolution of Treatment, Complications and Long-term Sequelae
  168. [168]

    Fawaz L, Badawi N, Hasan M et al.. “Impact of telemonitoring on glycemic control and quality of life in pediatric patients with type 1 diabetes, single center interventional control study.” BMC pediatrics (2026). PMID: 42332616 ↗

    L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  169. [169]

    Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N et al.. “Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis.” The Cochrane database of systematic reviews (2016). PMID: 26798030 ↗

    L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  170. [170]

    Lo C, Toyama T, Wang Y et al.. “Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.” The Cochrane database of systematic reviews (2018). PMID: 30246878 ↗

    L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  171. [171]

    Guo Y, Mei Y, Bongaerts B et al.. “(Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis.” The Cochrane database of systematic reviews (2026). PMID: 42318853 ↗

    L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  172. [172]

    Kim M, Park E. “Continuous Glucose Monitoring and Hypoglycaemia Risk During Paediatric DKA Treatment in the PICU: A Retrospective Cohort Study.” Diabetes, obesity & metabolism (2026). PMID: 42421174 ↗

    L3COHORTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  173. [173]

    Lim CE, Pasternak B, Eliasson B et al.. “Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Patients with Type 1 Diabetes: A Nationwide Register-Based Cohort Study.” The Lancet regional health. Europe (2026). PMID: 42306189 ↗

    L3COHORTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  174. [174]

    Bao Z, Hu J, Sun Y et al.. “Renal and cardiovascular outcomes and safety of SGLT2 inhibitors in patients aged ≥ 65 years with non-dialysis chronic kidney disease: a systematic review and meta-analysis of subgroup-level estimates derived from randomized trials.” BMC cardiovascular disorders (2026). PMID: 42420866 ↗

    L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  175. [175]

    Wang S, Zhang Y, Balati A et al.. “Effect of Sodium-glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39812177 ↗

    L1SR_MA_RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
  176. [176]

    Donovan LE, Feig DS, Lemieux P et al.. “A Randomized Trial of Closed-Loop Insulin Delivery Postpartum in Type 1 Diabetes.” Diabetes care (2023). PMID: 37824779 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  177. [177]

    Groop PH, Dandona P, Phillip M et al.. “Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.” The lancet. Diabetes & endocrinology (2020). PMID: 32946821 ↗

    L2RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  178. [178]

    Bosi E, Choudhary P, de Valk HW et al.. “Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.” The lancet. Diabetes & endocrinology (2019). PMID: 31047902 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  179. [179]

    Dandona P, Mathieu C, Phillip M et al.. “Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.” The lancet. Diabetes & endocrinology (2017). PMID: 28919061 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  180. [180]

    Garg SK, Henry RR, Banks P et al.. “Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.” The New England journal of medicine (2017). PMID: 28899222 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  181. [181]

    Gübeli A, Steiner N, Limacher A et al.. “Dapagliflozin's impact on hormonal regulation and ketogenesis in type 1 diabetes: a randomised controlled crossover trial.” Diabetologia (2025). PMID: 40629004 ↗

    L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
  182. [182]

    Peters AL, Buschur EO, Buse JB et al.. “Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.” Diabetes care (2015). PMID: 26078479 ↗

    L4OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  183. [183]

    AbuJlambo A, AbuZarifa M, Sawh RRR et al.. “Impact of Early Subcutaneous Basal Insulin With Intravenous Insulin Infusion for Diabetic Ketoacidosis and Glycaemic Outcomes: A Systematic Review and Meta-Analysis.” Endocrinology, diabetes & metabolism (2026). PMID: 42405473 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  184. [184]

    Mata E, Resende B, Castro M et al.. “Efficacy and Safety of Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta-Analysis.” Korean circulation journal (2026). PMID: 42204740 ↗

    L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
  185. [185]

    Fisher JN, Kitabchi AE. “A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis.” The Journal of clinical endocrinology and metabolism (1983). PMID: 6406531 ↗

    L1RCTCited in: History and Evolution of Treatment
  186. [186]

    Anderson JJA, Couper JJ, Giles LC et al.. “Effect of Metformin on Vascular Function in Children With Type 1 Diabetes: A 12-Month Randomized Controlled Trial.” The Journal of clinical endocrinology and metabolism (2017). PMID: 29040598 ↗

    L1RCTCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
  187. [187]

    Ho J, Nicolucci AC, Virtanen H et al.. “Effect of Prebiotic on Microbiota, Intestinal Permeability, and Glycemic Control in Children With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31188437 ↗

    L1RCTCited in: History and Evolution of Treatment
  188. [188]

    Hsia E, Seggelke S, Gibbs J et al.. “Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22685233 ↗

    L1RCTCited in: History and Evolution of Treatment
  189. [189]

    Kuhadiya ND, Ghanim H, Mehta A et al.. “Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2016). PMID: 27490915 ↗

    L1RCTCited in: History and Evolution of Treatment
  190. [190]

    Sherwood JS, Castellanos LE, O'Connor MY et al.. “Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis- Related Diabetes.” Diabetes care (2024). PMID: 37874987 ↗

    L1RCTCited in: History and Evolution of Treatment
  191. [191]

    Ghetti S, Kuppermann N, Rewers A et al.. “Cognitive Function Following Diabetic Ketoacidosis in Children With New-Onset or Previously Diagnosed Type 1 Diabetes.” Diabetes care (2020). PMID: 32962981 ↗

    L2RCTCited in: History and Evolution of Treatment
  192. [192]

    Beunen K, Gillard P, Van Wilder N et al.. “Advanced Hybrid Closed-Loop Therapy Compared With Standard Insulin Therapy Intrapartum and Early Postpartum in Women With Type 1 Diabetes: A Secondary Observational Analysis From the CRISTAL Randomized Controlled Trial.” Diabetes care (2024). PMID: 39331059 ↗

    L2RCTCited in: History and Evolution of Treatment
  193. [193]

    McAuley SA, Trawley S, Vogrin S et al.. “Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial.” Diabetes care (2022). PMID: 34844995 ↗

    L1RCTCited in: History and Evolution of Treatment
  194. [194]

    Pasqua MR, Jafar A, Kobayati A et al.. “Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial.” Diabetes care (2023). PMID: 36331522 ↗

    L1RCTCited in: History and Evolution of Treatment
  195. [195]

    . “Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience.” Diabetes care (2013). PMID: 23704676 ↗

    L1RCTCited in: History and Evolution of Treatment
  196. [196]

    Breton MD, Kanapka LG, Beck RW et al.. “A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes.” The New England journal of medicine (2020). PMID: 32846062 ↗

    L1RCTCited in: History and Evolution of Treatment
  197. [197]

    Fisher JN, Shahshahani MN, Kitabchi AE. “Diabetic ketoacidosis: low-dose insulin therapy by various routes.” The New England journal of medicine (1977). PMID: 406561 ↗

    L1RCTCited in: History and Evolution of Treatment
  198. [198]

    Kim JY, Jin SM, Kang ES et al.. “Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial.” Diabetologia (2024). PMID: 38634887 ↗

    L1RCTCited in: History and Evolution of Treatment
  199. [199]

    Voss TS, Vendelbo MH, Kampmann U et al.. “Substrate metabolism, hormone and cytokine levels and adipose tissue signalling in individuals with type 1 diabetes after insulin withdrawal and subsequent insulin therapy to model the initiating steps of ketoacidosis.” Diabetologia (2018). PMID: 30506451 ↗

    L1RCTCited in: History and Evolution of Treatment
  200. [200]

    Oskarsson P, Antuna R, Geelhoed-Duijvestijn P et al.. “Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.” Diabetologia (2017). PMID: 29273897 ↗

    L2RCTCited in: History and Evolution of Treatment, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
  201. [201]

    Svart MV, Rittig N, Kampmann U et al.. “Metabolic effects of insulin in a human model of ketoacidosis combining exposure to lipopolysaccharide and insulin deficiency: a randomised, controlled, crossover study in individuals with type 1 diabetes.” Diabetologia (2017). PMID: 28389705 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis, Natural History and Prevention
  202. [202]

    Akturk HK, Alkanani A, Zhao Z et al.. “PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.” The Journal of clinical endocrinology and metabolism (2018). PMID: 30124874 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment, Complications and Long-term Sequelae
  203. [203]

    Valerio D. “Acute diabetic abdomen in childhood.” Lancet (London, England) (1976). PMID: 54584 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  204. [204]

    Huang Z, Wu Y, Tang C et al.. “A Multicentre, Randomised, Controlled, Open-Label Study of Continuous Subcutaneous Insulin Infusion Plus Henagliflozin for Treating Type 2 Diabetes Mellitus Patients With Severe Hyperglycaemia.” Diabetes, obesity & metabolism (2026). PMID: 41853855 ↗

    L1RCTCited in: History and Evolution of Treatment
  205. [205]

    Baek G, Lee E. “Effectiveness of a virtual reality simulation based on experiential learning theory for enhancing diabetic ketoacidosis management competencies: a randomized controlled trial.” BMC medical education (2026). PMID: 41814271 ↗

    L1RCTCited in: History and Evolution of Treatment
  206. [206]

    Jendle JH, Garg SK, Thivolet C et al.. “Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial.” Frontiers in endocrinology (2025). PMID: 41488135 ↗

    L1RCTCited in: History and Evolution of Treatment
  207. [207]

    Lundbaek K, Hansen AP, Orskov H et al.. “Failure of somatostatin to correct manifest diabetic ketoacidosis.” Lancet (London, England) (1976). PMID: 55530 ↗

    L4OTHERCited in: History and Evolution of Treatment
  208. [208]

    Liu Y, Wang Y, Wu W et al.. “Glycaemic Outcomes of a Novel Model-Predictive-Control-Based Hybrid Closed-Loop System in Chinese Adolescents and Adults With Type 1 Diabetes: A Multicentre Pivotal Trial.” Diabetes, obesity & metabolism (2026). PMID: 41913542 ↗

    L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  209. [209]

    Aly HH, Fouda EM, Kotby AA et al.. “COVID-19-Related Multisystem Inflammatory Syndrome in Children Presenting With New-Onset Type 1 Diabetes in Severe Ketoacidosis: A Case Series.” Diabetes care (2022). PMID: 35113159 ↗

    L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  210. [210]

    Nimri R, Rachmiel M, Yackobovitch-Gavan M et al.. “Symptoms and Glycemic Control in Young People With Type 1 Diabetes Following SARS-CoV-2 Infection: An Observational Study.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35524727 ↗

    L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  211. [211]

    Chao LC, Vidmar AP, Georgia S. “Spike in Diabetic Ketoacidosis Rates in Pediatric Type 2 Diabetes During the COVID-19 Pandemic.” Diabetes care (2021). PMID: 33905347 ↗

    L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  212. [212]

    Keiner ES, Slaughter JC, Datye KA et al.. “COVID-19 Exacerbates Insulin Resistance During Diabetic Ketoacidosis in Pediatric Patients With Type 1 Diabetes.” Diabetes care (2022). PMID: 35944264 ↗

    L3OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
  213. [213]

    Garabedian C, Sénat MV, Sananès N et al.. “[Preexisting diabetes: Expert consensus from the College of French Gynecologists and Obstetricians and from the French Society of Diabetology].” Gynecologie, obstetrique, fertilite & senologie (2025). PMID: 41365423 ↗

    L1GUIDELINECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  214. [214]

    Briones-Claudett KH, Benites-Solis J, Delgado-Cedeño P et al.. “Case Report: High-altitude exposure and severe respiratory infection precipitating diabetic ketoacidosis: new-onset ketosis-prone diabetes unmasked by physiological stress.” Frontiers in medicine (2026). PMID: 41836962 ↗

    L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  215. [215]

    Wu Y, Deng H, Sun J et al.. “Case Report: Diabetic ketoacidosis in a patient with Klinefelter syndrome: a rare and complex presentation.” Frontiers in endocrinology (2026). PMID: 41613957 ↗

    L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  216. [216]

    Zhang K, Wang Y, Chen S et al.. “Cohen syndrome with novel VPS13B variants presenting as early-onset diabetes: a case report.” Acta diabetologica (2026). PMID: 41591480 ↗

    L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
  217. [217]

    Balsells M, García-Patterson A, Gich I et al.. “Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19808847 ↗

    L1SR_OBSCited in: Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
  218. [218]

    Lin CH, Yeh NC, Wang JJ et al.. “Effect of Chronic Pancreatitis on Complications and Mortality in DM Patients: A 10-year Nationwide Cohort Study.” The Journal of clinical endocrinology and metabolism (2020). PMID: 31974550 ↗

    L2COHORTCited in: Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  219. [219]

    Haddad N, Farhat N, Gravel CA et al.. “Antipsychotic Drugs and the Risk of Diabetic Complications: A Systematic Review of Observational Studies.” Journal of clinical medicine (2026). PMID: 42123269 ↗

    L2SR_OBSCited in: Complications and Long-term Sequelae
  220. [220]

    Anesini MB, Pinto M, Bellezza M et al.. “Intentional Insulin Omission (Diabulimia) in Patients with Insulin-Dependent Diabetes: An Eating Disorder? A Systematic Review.” Journal of clinical medicine (2026). PMID: 42123251 ↗

    L2SR_OBSCited in: Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
  221. [221]

    Li L, Shen S, Ouyang J et al.. “Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22419704 ↗

    L4TRIAL_NONRANDOMCited in: Prognosis, Natural History and Prevention
  222. [222]

    Dunne JL, Koralova A, Sutphin J et al.. “Parent and Pediatrician Preferences for Type 1 Diabetes Screening in the U.S.” Diabetes care (2020). PMID: 33303637 ↗

    L5OTHERCited in: Prognosis, Natural History and Prevention
  223. [223]

    McQueen RB, Geno Rasmussen C, Waugh K et al.. “Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado.” Diabetes care (2020). PMID: 32327420 ↗

    L2OTHERCited in: Prognosis, Natural History and Prevention
  224. [224]

    Bapat P, Budhram DR, Bakhsh A et al.. “Longitudinal Determination of Diabetes Complications and Other Clinical Variables as Risk Factors for Diabetic Ketoacidosis in Type 1 Diabetes.” Diabetes care (2025). PMID: 39950992 ↗

    L2OTHERCited in: Prognosis, Natural History and Prevention
  225. [225]

    Wang CA, Wang WJ, Chen JY et al.. “Impact of sodium-glucose cotransporter-2 inhibitors on clinical outcomes in patients with type 1 diabetes after dialysis-requiring acute kidney injury: a real-world cohort study.” Diabetes research and clinical practice (2026). PMID: 42049097 ↗

    L2COHORTCited in: Prognosis, Natural History and Prevention
  226. [226]

    Chia JE, Ang SP, Wu S et al.. “Age and sex differences in diabetic ketoacidosis outcomes in type 1 diabetes: a national cohort study.” BMJ open diabetes research & care (2026). PMID: 41698751 ↗

    L2COHORTCited in: Prognosis, Natural History and Prevention
  227. [227]

    Bongaerts B, Leuwer A, Sadiq F et al.. “Models of care for children and adolescents with type 1 diabetes in low- and middle-income countries: a scoping review.” The Cochrane database of systematic reviews (2025). PMID: 40927968 ↗

    L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention
  228. [228]

    Cahn A, Mosenzon O, Wiviott SD et al.. “Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.” Diabetes care (2019). PMID: 31843945 ↗

    L1RCTCited in: Special Populations, Pregnancy and Fertility
  229. [229]

    Oktavian P, Kencono Wungu CD, Amin IM et al.. “Automated Insulin Delivery in Young Children with Type 1 Diabetes: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41877382 ↗

    L2SR_OBSCited in: Special Populations, Pregnancy and Fertility
  230. [230]

    Everett EM, Copeland TP, Moin T et al.. “National Trends in Pediatric Admissions for Diabetic Ketoacidosis, 2006-2016.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33942077 ↗

    L2OTHERCited in: Special Populations, Pregnancy and Fertility
  231. [231]

    Parikh HM, Remedios CL, Hampe CS et al.. “Data Mining Framework for Discovering and Clustering Phenotypes of Atypical Diabetes.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36314086 ↗

    L5OTHERCited in: Special Populations, Pregnancy and Fertility
  232. [232]

    Donovan LE, Lemieux P, Yamamoto JM et al.. “Intrapartum and Early Postpartum Use of Automated Insulin Delivery in Type 1 Diabetes: A Prespecified Analysis of the CIRCUIT Randomized Controlled Trial.” Diabetes care (2026). PMID: 42201836 ↗

    L1RCTCited in: Special Populations, Pregnancy and Fertility
  233. [233]

    Maahs DM, Hermann JM, DuBose SN et al.. “Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries.” Diabetologia (2014). PMID: 24893863 ↗

    L2OTHERCited in: Special Populations, Pregnancy and Fertility
  234. [234]

    Matejko B, Cyranka K, Suduł P et al.. “Metabolic and vascular outcomes after transition to the MiniMed 780G system in adults ≥65 years with type 1 diabetes: a randomised, single-centre study.” Diabetologia (2026). PMID: 42347980 ↗

    L1OTHERCited in: Special Populations, Pregnancy and Fertility
  235. [235]

    Kallas-Koeman MM, Kong JM, Klinke JA et al.. “Insulin pump use in pregnancy is associated with lower HbA1c without increasing the rate of severe hypoglycaemia or diabetic ketoacidosis in women with type 1 diabetes.” Diabetologia (2014). PMID: 24434960 ↗

    L2OTHERCited in: Special Populations, Pregnancy and Fertility
  236. [236]

    Turtinen M, Härkönen T, Parkkola A et al.. “Characteristics of familial type 1 diabetes: effects of the relationship to the affected family member on phenotype and genotype at diagnosis.” Diabetologia (2019). PMID: 31346657 ↗

    L4OTHERCited in: Special Populations, Pregnancy and Fertility
  237. [237]

    Kim JY, Kim S, Kim JH. “Association between Continuous Glucose Monitoring and Risk of Acute Diabetes-Related Complications in Pediatric Type 1 Diabetes Mellitus: A Nationwide Cohort Study.” Diabetes & metabolism journal (2026). PMID: 42014052 ↗

    L2COHORTCited in: Special Populations, Pregnancy and Fertility

Revision History

All updates applied to this page

Loading revisions…